Everything You Ever Wanted to Know About Race: And Why That’s Important for Evolutionary Medicine
Thursday, October 1st at 12pm EDT
Join us for a conversation with Joseph L. Graves Jr., Professor of Biological Sciences at the Joint School for Nanoscience and Nanoengineering, administered by North Carolina A&T State University and UNC Greensboro. Ongoing confusion concerning the nature and significance of human biological variation exists within the lay public, medical practitioners, and biomedical researchers. This occurs despite the fact that a core principle of evolutionary science is the importance of variation. This talk addresses how evolutionary principles can be better applied to understand health disparities associated with socially defined race. Attendees are encouraged to read Graves 2019, “African Americans in evolutionary science: where we have been, and what’s next” and Graves 2018, “Biological Theories of Race Beyond the Millennium” (in Suzuki and Von Vacano, Reconsidering Race: Social Science Perspectives on Racial Categories in the Age of Genomics), which will be shared upon registration. Sign up here for the meeting link.
Assessing SARS-CoV-2 susceptibility in 400 species with comparative genomics
Tuesday, October 6th at 12pm EDT
Join us for a conversation with Elinor Karlsson, Associate Professor in Bioinformatics and Integrative Biology at the University of Massachusetts Medical School and the director of the Vertebrate Genomics Group at the Broad Institute of MIT and Harvard. SARS-CoV-2, the virus that causes COVID-19, is a zoonotic pathogen that readily infects some non-human species, posing a risk to humans, if viral reservoirs are established in other species, and to other species, particularly those already endangered. Data on susceptibility and pathology in non-human species is sparse, with natural infection documented in fewer than a dozen species, but genomic datasets are far more substantial. We compiled genomic data for over 400 species and used the sequence of ACE2, the host receptor protein, to make a prediction of SARS-CoV-2 susceptibility. We also show that the viral binding domain of ACE2 is enriched for signals of natural selection in bats, the proposed source of the progenitor virus. By leveraging existing data resources, we completed this work in just four weeks in the midst of a global pandemic. While the risk predictions are preliminary, this work demonstrates how open genomic resources can be leveraged to address questions never envisioned in their original design. Sign up here for the meeting link.
Survival of the Friendliest
Tuesday, October 13th at 12pm EDT
Join us for a conversation with Brian Hare, Professor of Evolutionary Anthropology at Duke University. The only way to understand what it is to be human is to know what it is like to be not human. In this talk we will explore the minds of our closest relatives, bonobos and chimpanzees, and dogs — our closest friend. We will look at how these animals help us understand what makes us human, and how our minds came to be. We will arrive at the idea that it was friendliness that powerfully shaped both the bodies and minds of bonobos and dogs during their evolution. We will then consider if our own species evolved due to selection for friendliness. We will argue that comparing our friendly nature to other animals solves the paradox of human kindness and cruelty and points to the need for cross-group friendships to encourage a friendlier future. These ideas are explored in Hare’s new book, Survival of the Friendliest: Understanding Our Origins and Rediscovering Our Common Humanity. Sign up here for the meeting link.
How recent characterizations of somatic mutations in humans inform an evolutionary understanding of aging and cancer
Monday, October 19th at 1pm EDT
Join us for a conversation with James DeGregori, Courtenay C. And Lucy Patten Davis Endowed Chair in Lung Cancer Research at the University of Colorado Anschutz Medical Campus. In the last five years, multiple studies have demonstrated that apparently healthy tissues in humans are patchworks of clones bearing somatic mutations, and the sizes and frequencies of these clones increases dramatically in old age. Often, there is clear evidence for positive selection for variants, which are frequently in genes frequently mutated in cancers, and yet the vast (VAST!) majority of these mutation-bearing clones will never develop into a cancer. We will discuss the implications of these findings for different evolutionary theories of aging and cancer. Sign up here for the meeting link.
Pathogen selection for HLA gene diversity and its consequences for autoimmunity and cancer immunotherapy
Tuesday, October 27th at 1pm EDT
Join us for a conversation with Tobias L. Lenz of the Research Group for Evolutionary Immunogenomics at the Max Planck Institute for Evolutionary Biology in Ploen, Germany. Pathogen-mediated selection is a major driver of human evolution in general and of immune gene diversity specifically. A key component of the adaptive immune system are the human leukocyte antigen (HLA) genes, coding for molecules that present antigenic peptides to immune effector cells. The exceptional polymorphism at the HLA gene is assumed to reflect the need for diverse antigen presentation. However, an optimal immune response requires a delicate balance of maximizing recognition of pathogens while minimizing damage to self tissue by the immune machinery. As HLA molecules present both non-self and self antigens, depending on which antigens are presented by an individual’s HLA variants, this can trigger either pathogen resistance or autoimmunity. HLA-presentation of a broader antigen repertoire should thus be beneficial for pathogen recognition, but might also increase the risk for autoimmunity, leading to antagonistic selective pressures that shape the optimal antigen repertoire and thus HLA diversity in an individual.
Here Dr. Lenz will discuss this evolutionary trade-off for individual HLA diversity and present some examples from his work on the role of pathogens in the evolution of HLA diversity, but also on its consequences for autoimmunity and its role in immune checkpoint blockade therapy against cancer, a striking example for the success of evolutionary medicine. Attendees are encouraged to read Pierini and Lenz 2018, “Divergent allele advantage at human MHC genes: signatures of past and ongoing selection” and Chowell et al. 2019, “Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.” Sign up here for the meeting link.
Club EvMed conversation led by Dan Blumstein (UCLA)
Thursday, November 12th at 12pm EST
Full details to be announced soon, but you can register in advance here.
Club EvMed conversation led by Sylvia Cremer (Institute of Science and Technology, Austria)
Tuesday, November 17th
Full details and registration link to be announced soon.
Club EvMed conversation led by Phil Starks (Tufts University)
week of December 7th
Full details and registration link to be announced soon.